Research programme: chemokine receptor antagonists - Sanofi GenzymeAlternative Names: AMD 887; CXCR4 antagonists - Sanofi Genzyme
Latest Information Update: 16 Dec 2016
At a glance
- Originator Genzyme Corporation
- Mechanism of Action CCR5 receptor antagonists; CXCR4 receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Asthma; Cancer; HIV infections; Rheumatoid arthritis